GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
32
c/orforglipron·posted 2 months ago by u/kavya_radich

switched from 10mg to 15mg and constipation got better, not worse

Question

Something I keep coming back to: switched from 10mg to 15mg and constipation got better, not worse.

Since the title puts numbers in the shop window: 10mg and 15mg.

Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.

Went looking for independent testing on this and found essentially nothing, which was clarifying.

Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.

48 up / 16 down75% upvoted14 commentsid 11k3s518 May 2026

14 comments

14 in this archive, depth 4

best — the order this archive was captured in

u/bruno_dumitru5 points·2 months ago

Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.

replysharereportpermalink
u/rasmus_petrescu2 points·2 months ago

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.

replysharereportpermalink
u/batch_number_bertievetting3 points·2 months ago

Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.

replysharereportpermalink
u/kavya_radichOP2 points·2 months ago

no food and water restrictions is the practical difference people care about

replysharereportpermalink
u/dario_boateng1 point·2 months ago·edited

no food and water restrictions is the practical difference people care about

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

replysharereportpermalink
u/flair_enthusiast4 points·2 months ago

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

replysharereportpermalink
u/phase_two_peteMOD2 points·2 months ago

Standing reminder: unapproved compound, research material is not for human use, and no schedules for other members.

replysharereportpermalink
u/meera_sandvik2 points·2 months ago

Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.

replysharereportpermalink
u/hedda_ekstrom1 point·2 months ago

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

replysharereportpermalink
u/kavya_radichOP1 point·2 months ago·edited

Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.

replysharereportpermalink
u/ines_lindqvist1 point·2 months ago

a non-peptide agonist does not degrade the way a peptide does

replysharereportpermalink
u/nils_ferreira1 point·2 months ago

Compared milligram figures across two completely different molecule classes in a comment.

Adding the standing caveat — unapproved, and research material is not for human use.

replysharereportpermalink
u/purity_pedantanalytical2 points·2 months ago

Why "oral" is doing two completely different jobs in the sentences people write here.

Oral semaglutide is a peptide co-formulated with an absorption enhancer, which is why it comes with food and water timing requirements. This compound is a non-peptide small molecule that activates the same receptor, formulated as an ordinary tablet.

The practical consequences differ enormously: no timing constraints, a conventional manufacturing route, different stability behaviour, and a different analytical problem for anybody trying to verify identity or purity. Whenever a thread here compares the two, check which sense of "oral" each half is using.

replysharereportpermalink
u/niels_norgaard1 point·2 months ago

Daily dosing, so what does the exposure profile look like across the day?

replysharereportpermalink
About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.